MacroGenics (Nasdaq: MGNX) announced that President and CEO Eric Risser will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, at 10:30 a.m. ET.
A live webcast and 30-day replay will be available in the Investor Relations section of MacroGenics' website.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – MGNX
+2.16%2.2x vol
79 alerts
+2.16%News Effect
+21.7%Peak in 36 hr 24 min
+$6MValuation Impact
$276.17MMarket Cap
2.2xRel. Volume
On the day this news was published, MGNX gained 2.16%, reflecting a moderate positive market reaction.
Argus tracked a peak move of +21.7% during that session.
Our momentum scanner triggered 79 alerts that day, indicating high trading interest and price volatility.
This price movement added approximately $6M to the company's valuation, bringing the market cap to $276.17M at that time.
Trading volume was elevated at 2.2x the daily average, suggesting notable buying interest.
This announcement centers on MacroGenics’ participation in a targeted oncology investor forum, offer...
Analysis
This announcement centers on MacroGenics’ participation in a targeted oncology investor forum, offering management another venue to discuss its antibody-based cancer programs and strategy. In the months leading up to this, the company reported 2025 results, extended its cash runway, and entered significant asset and royalty deals, including a planned $122.5 million manufacturing sale. Investors may watch for any new commentary on pipeline timelines, partnership economics, and capital allocation during the webcast and 30-day replay period.
Key Figures
Event date:May 20, 2026Event time:10:30 a.m. ETArchive duration:30 days
3 metrics
Event dateMay 20, 2026Date of Stifel 2026 Virtual Targeted Oncology Forum fireside chat
Event time10:30 a.m. ETScheduled start time of MacroGenics fireside chat
Archive duration30 daysLength of time webcast replay will remain on company website
Announcement of multiple March 2026 investor conference appearances and webcasts.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent substantial positive reactions followed strategic monetization and earnings news, while clinical and conference updates have had muted or mixed impact.
Recent Company History
Over recent months, MacroGenics has focused on monetizing assets and strengthening liquidity, including an agreement to sell its GMP manufacturing operations for $122.5 million and an expanded ZYNYZ royalty deal with upfront and potential milestone payments. Financial results for 2025 and early 2026 highlighted improved revenue, reduced expenses, and an extended cash runway. Clinical progress included removal of an FDA partial hold on the LINNET study. Today’s investor-forum participation continues a pattern of active investor outreach following these strategic and clinical milestones.
Key Terms
biopharmaceutical, antibody-based therapeutics, oncology, webcast, +1 more
5 terms
biopharmaceuticalmedical
"MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing"
A biopharmaceutical is a medicine made from living organisms or their components—such as proteins, cells or genetic material—rather than chemically synthesized compounds. For investors, these products can command high prices and long patent protection but also carry bigger development, manufacturing and regulatory risks; think of them like handcrafted, high-tech products that can generate strong returns if they work, but are costly and complex to produce.
antibody-based therapeuticsmedical
"developing innovative antibody-based therapeutics for the treatment of cancer"
Antibody-based therapeutics are medicines made from or modeled on antibodies, the proteins the immune system uses to recognize and attach to specific disease targets. Think of them as guided missiles that home in on a particular molecule on a virus, cancer cell or other harmful agent, which can improve effectiveness and reduce side effects. Investors watch them because they can command premium prices, carry patent value and regulatory risk, and often drive significant company growth or volatility depending on clinical and approval outcomes.
oncologymedical
"Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026"
Oncology is the branch of medicine focused on understanding, diagnosing, and treating cancer, including the development and testing of drugs, therapies, and screening methods. It matters to investors because advances, trial results, regulatory approvals, or setbacks in cancer research can dramatically change the value of companies and the size of potential markets—think of oncology news as weather reports that help investors steer financial decisions in a high-stakes field.
webcasttechnical
"A webcast of the presentation may be accessed under "Events & Presentations""
A webcast is a live or recorded online event where people watch or listen to presentations, announcements, or performances through the internet. It’s like a TV broadcast but over the internet, allowing viewers from anywhere to tune in in real time or later. Webcasts are important because they let companies share information quickly and widely with audiences around the world.
investor relationsfinancial
"in the Investor Relations section of MacroGenics' website"
Investor relations is the communication process between a company and its current or potential investors. It involves sharing information about the company's performance, strategies, and outlook to help investors make informed decisions. Effective investor relations build trust and transparency, similar to a clear conversation between a business and someone considering investing, ensuring both parties understand each other's interests and expectations.
ROCKVILLE, MD, May 14, 2026 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced that Eric Risser, President and CEO of MacroGenics, will participate in a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on Wednesday, May 20, 2026 at 10:30 a.m. ET.
A webcast of the presentation may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm. The Company will maintain an archived replay of the webcasts on its website for 30 days.
About MacroGenics, Inc. MacroGenics (the Company) is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.
When will MacroGenics (MGNX) present at the Stifel 2026 Virtual Targeted Oncology Forum?
MacroGenics will present on May 20, 2026, at 10:30 a.m. ET. According to MacroGenics, President and CEO Eric Risser will participate in a fireside chat during the Stifel 2026 Virtual Targeted Oncology Forum webcast.
Who will represent MacroGenics (MGNX) at the Stifel 2026 Virtual Targeted Oncology Forum?
MacroGenics will be represented by Eric Risser, its President and CEO. According to MacroGenics, Risser will join a fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum on May 20, 2026, at 10:30 a.m. ET.
How can investors access the MacroGenics (MGNX) webcast for the Stifel 2026 oncology forum?
Investors can access the live webcast via the Investor Relations section of MacroGenics’ website. According to MacroGenics, the webcast is listed under “Events & Presentations” and will feature a fireside chat with President and CEO Eric Risser.
Will a replay of the MacroGenics (MGNX) Stifel 2026 forum presentation be available?
Yes, a replay will be available for 30 days on the MacroGenics website. According to MacroGenics, the archived webcast can be accessed in the Investor Relations “Events & Presentations” section following the May 20, 2026 fireside chat.
What is the focus of MacroGenics (MGNX) as it participates in the Stifel 2026 oncology forum?
MacroGenics focuses on developing innovative antibody-based therapeutics for cancer treatment. According to MacroGenics, its leadership, including President and CEO Eric Risser, will discuss the company’s oncology work during the fireside chat at the Stifel 2026 Virtual Targeted Oncology Forum.
